Indication
Evenity is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
Loading your page…
Loading your page…
Osteoporosis
Marketing Authorisation Holder: UCB Pharma S.A.
EMA Authorisation: 09/12/2019
INN: romosozumab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Evenity: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.